University of Pittsburgh Seal Link to Homepage
Archive Service Center Link University Library System Link

Drug Immunosuppression Appendix

# Article Information # of Cites
1Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A: FK 506 for human liver, kidney and pancreas transplantation. Lancet 2:1000-1004, 1989.
http://d-scholarship.pitt.edu/4409/
781
2Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ: The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 124:301-318, 1967.
http://d-scholarship.pitt.edu/3517/
379
3Starzl TE, Klintmalm GBG, Porter KA, Iwatsuki S, Schroter GPJ: Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 305:266-269, 1981.
http://d-scholarship.pitt.edu/3856/
365
4Klintmalm GBG, Iwatsuki S, Starzl TE: Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1:470-471, 1981.
http://d-scholarship.pitt.edu/3853/
283
5Starzl TE, Weil R III, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA: The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet 151:17-26, 1980.
http://d-scholarship.pitt.edu/3839/
277
6 Klintmalm GBG, Iwatsuki S, Starzl TE: Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 32:488-489, 1981.
http://d-scholarship.pitt.edu/3858/
245
7Todo S, Fung JJ, Starzl TE, Tzakis A, Demetris AJ, Kormos R, Jain A, Alessiani M, Takaya S: Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 212:295-305, 1990.
http://d-scholarship.pitt.edu/4494/
225
8Iwatsuki S, Starzl TE, Todo S, Gordon RD, Esquivel CO, Tzakis AG, Makowka L, Marsh JW, Koneru B, Stieber A, Klintmalm G, Husberg B: Experience in 1,000 liver transplants under cyclosporine-steroid therapy: A survival report. Transplant Proc 20:498-504, 1988.
http://d-scholarship.pitt.edu/4231/
222
9Mazariegos GV, Reyes J, Marino I, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE: Weaning of immunosuppression in liver transplant recipients. Transplantation 63:243-249, 1997.
http://d-scholarship.pitt.edu/5315/
213
10Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S: Kidney transplantation under FK 506. JAMA 264:63-67, 1990.
http://d-scholarship.pitt.edu/4482/
209
11Iwasaki Y, Porter KA, Amend JR, Marchioro TL, Zuhlke V, Starzl TE: The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet 124:1-24, 1967.
http://d-scholarship.pitt.edu/3515/
179
12Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanan R, Makowka L, Starzl TE: Immunosuppression of canine, monkey, and baboon allografts by FK 506 with special reference to synergism with other drugs, and to tolerance induction. Surgery 104:239-249, 1988.
http://d-scholarship.pitt.edu/4245/
179
13Starzl TE, Klintmalm GBG, Weil R III, Porter KA, Iwatsuki S, Schroter GPJ, Fernandez-Bueno C, MacHugh N: Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 153:486-494, 1981.
http://d-scholarship.pitt.edu/3855/
178
14Starzl TE, Porter KA, Andres G, Halgrimson CG, Hurwitz R, Giles G, Terasaki PI, Penn I, Schroter GT, Lilly J, Starkie SJ, Putnam CW: Long-term survival after renal transplantation in humans: With special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG, and recipient malignancy. Ann Surg 172:437-472, 1970.
http://d-scholarship.pitt.edu/3605/
178
15Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE: Adverse effects associated with the use of FK 506. Transplant Proc 23:3105-3108, 1991.
http://d-scholarship.pitt.edu/4655/
168
16Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Rhandhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE: FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57:860-865, 1994.
http://d-scholarship.pitt.edu/5001/
142
17Murase N, Demetris AJ, Matsuzaki T, Yagihasi A, Todo S, Fung J, Starzl TE: Long survival in rats after multivisceral versus isolated small bowel allotransplantation under FK 506. Surgery 110:87-98, 1991.
http://d-scholarship.pitt.edu/4584/
139
18Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, McCauley J, Carroll P, Ricordi C, Demetris AJ, Mitchell S, Jain A, Iwaki Y, Kobayashi M, Reyes J, Todo S, Hakala TR, Simmons RL, Starzl TE: FK506 in clinical kidney transplantation. Transplant Proc 23:3065-3067, 1991.
http://d-scholarship.pitt.edu/4683/
136
19Murase N, Starzl TE, Demetris AJ, Valdivia L, Tanabe M, Cramer D, Makowka L: Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation 55:701-708, 1993.
http://d-scholarship.pitt.edu/4826/
130
20Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 17(1):60-68, 1993.
http://d-scholarship.pitt.edu/4915/
129
21Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE: The side effects of FK 506 in humans. Transplant Proc 22:35-36, 1990.
http://d-scholarship.pitt.edu/4456/
128
22Venkataramanan R, Jain A, Cadoff E, Warty V, Krajack A, Imventarza O, Todo S, Fung JJ, Starzl TE: Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 22:52-56, 1990.
http://d-scholarship.pitt.edu/4462/
128
23Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, Makowka L, Starzl TE: Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: Synergism with cyclosporine A. Transplant Proc 19:40-44, 1987.
http://d-scholarship.pitt.edu/4191/
117
24Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, Takaya S, Todo S, Tzakis A, Van Thiel D, Shannon W, Starzl TE: Neurological complications of FK 506. Transplant Proc 23:3175-3178, 1991.
http://d-scholarship.pitt.edu/4649/
115
25Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE: Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506. Transplant Proc 22:6-12, 1990.
http://d-scholarship.pitt.edu/4450/
114
26Hoffman AL, Makowka L, Banner B, Cai X, Cramer DV, Pascualone A, Todo S, Starzl TE: The use of FK 506 for small intestine allotransplantation: Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation 49:483-490, 1990.
http://d-scholarship.pitt.edu/4443/
114
27Kashiwagi N, Brantigan CO, Brettschneider L, Groth CG, Starzl TE: Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med 68:275-286, 1968.
http://d-scholarship.pitt.edu/3540
111
28Starzl TE, Marchioro TL, Rowlands DT Jr, Kirkpatrick CH, Wilson WEC, Rifkind D, Waddell WR: Immunosuppression after experimental and clinical homotransplantation of the liver. Ann Surg 160:411-439, 1964.
http://d-scholarship.pitt.edu/3469/
108
29Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, Murase N, Zeevi A, Girnita A, Metes D, Ness R, Bass DC, Demetris AJ, Fung JJ, Marcos A, Starzl TE: Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 200:505-515, 2005.
http://d-scholarship.pitt.edu/5592/
108
30Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE: FK 506 - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 128:781-785, 1992.
http://d-scholarship.pitt.edu/4812/
106
31Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE: Conversion of liver allograft recipients from cyclosporine to FK 506 immunosuppressive therapy-A clinicopathologic study of 96 patients. Transplantation 53:1056-1062, 1992.
http://d-scholarship.pitt.edu/4754/
103
32Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Fung JJ, McCauley J, Randhawa P, Demetris AJ, Irish W, Mitchell S, Hakala TR, Simmons RL, Starzl TE: A prospective, randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 59:485-490, 1995.
http://d-scholarship.pitt.edu/5065/
98
33Pham SM, Kormos RL, Hattler BG, Kawai A, Tsamandas AC, Demetris AJ, Murali S, Fricker FJ, Chang HC, Jain AB, Starzl TE, Hardesty RL, Griffith BP: A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate term results. J Thoracic Cardiovascular Surg 111:764-772, 1996.
http://d-scholarship.pitt.edu/5245/
98
34Griffith BP, Bando K, Hardesty RL, Armitage JM, Keenan RJ, Paradis IL, Yousem SA, Komatsu K, Konishi H, Fung JJ, Starzl TE: Prospective randomized trial of FK 506 versus cyclosporine after human pulmonary transplantation. Transplantation 57:848-851, 1994.
http://d-scholarship.pitt.edu/4954/
97
35Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, Takaya S, Todo S, Shannon WD, Starzl TE: The effect of graft function on FK506 plasma levels, doses, and renal function, with particular reference to the liver. Transplantation 52:71-77, 1991.
http://d-scholarship.pitt.edu/4589/
96
36Murase N, Todo S, Lee P-H, Lai HS, Chapman F, Nalesnik MA, Makowka L, Starzl TE: Heterotopic heart transplantation in the rat under FK-506 alone or with cyclosporine. Transplant Proc 19:71-75, 1987.
http://d-scholarship.pitt.edu/4157/
95
37Todo S, Fung JJ, Demetris AJ, Jain A, Venkataramanan R, Starzl TE: Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc 22:13-16, 1990.
http://d-scholarship.pitt.edu/4451/
93
38Fung JJ, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl TE: Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506. Transplant Proc 22:6-12, 1990.
http://d-scholarship.pitt.edu/4450/
93
39Thomson AW and Starzl TE: New immunosuppressive drugs: Mechanistic insights and potential therapeutic advances. Immunological Reviews 136:71-98, 1993.
http://d-scholarship.pitt.edu/5025/
93
40Jain A, Venkatarmanana R, Fung JJ, Gartner JC, Lever J, Balan V, Warty V, Starzl TE: Pregnancy after liver transplantation under tacrolimus. Transplantation 64:559-565, 1997.
http://d-scholarship.pitt.edu/5369/
93
41Mehta M, Venkataramanan R, Burckart G, Ptachcinski R, Delamos B, Staschak S, Van Thiel D, Shaw B, Iwatsuki S, Starzl TE: Effect of bile on cyclosporine absorption in liver transplant patients. Br J Clin Pharmacol 25:579-584, 1988.
http://d-scholarship.pitt.edu/4206/
90
42McCauley J, Fung JJ, Jain A, Todo S, Starzl TE: The effects of FK 506 upon renal function after liver transplantation. Transplant Proc 22:17-20, 1990.
http://d-scholarship.pitt.edu/4452/
90
43Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, deVera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE: Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 78:966-971, 2004.
http://d-scholarship.pitt.edu/5589/
87
44Jain A, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, Starzl TE: Effect of hepatic dysfunction and T-tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 22:57-59, 1990.
http://d-scholarship.pitt.edu/4463/
87
45Shapiro R, Jordan M, Fung J, McCauley J, Johnston J, Iwaki Y, Tzakis A, Hakala T, Todo S, Starzl TE: Kidney transplantation under FK 506 immunosuppression. Transplant Proc 23:920-923, 1991.
http://d-scholarship.pitt.edu/4544/
87
46Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE: New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23:3169-3170, 1991.
http://d-scholarship.pitt.edu/4682/
84
47 Starzl TE, Porter KA, Iwasaki Y, Marchioro TL, Kashiwagi N: The use of antilymphocyte globulin in human renal homotransplantation. In: Antilymphocytic Serum (GEW Wolstenholme, M O'Connor, eds) J and A Churchill Limited, London, 1967, pp. 4-34.
http://d-scholarship.pitt.edu/3524/
82
48Starzl TE, Iwatsuki S, Klintmalm G, Schroter GPJ, Weil R III, Koep LJ, Porter KA: Liver transplantation, 1980, with particular reference to cyclosporin A. Transplant Proc 13:281-285, 1981.
http://d-scholarship.pitt.edu/3848/
82
49Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE: Tacrolimus (FK 506)a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 90(3):455-459, 1995.
http://d-scholarship.pitt.edu/5189/
82
50Starzl TE, Groth CG, Terasaki PI, Putnam CW, Brettschneider L, Marchioro TL: Heterologous antilymphocyte globulin, histocompatibility matching, and human renal homotransplantation. Surg Gynecol Obstet 126:1023-1035, 1968.
http://d-scholarship.pitt.edu/3542/
81
51Jordan ML, Shapiro R, Naraghi R, Smith D, Vivas C, Gritsch HA, Scantlebury V, Rhandhawa P, Demetris AJ, Fung JJ, Starzl TE: Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 28:2119-2120, 1996.
http://d-scholarship.pitt.edu/5312/
80
52Todo S, Demetris A, Ueda Y, Imventarza O, Cadoff E, Zeevi A, Starzl TE: Renal transplantation in baboons under FK 506. Surgery 106:444-451, 1989.
http://d-scholarship.pitt.edu/4347/
78
53Coburg AJ, Gray SH, Katz FH, Penn I, Halgrimson C, Starzl TE: Disappearance rates and immunosuppression of intermittent intravenously administered prednisolone in rabbits and human beings. Surg Gynecol Obstet 131:933-942, 1970.
http://d-scholarship.pitt.edu/3616/
76
54Todo S, Demetris AJ, Ueda Y, Imventarza O, Okuda K, Casavilla A, Cemaj S, Ghalab A, Mazzaferro V, Rhoe BS, Tonghua Y, Makowka L, Starzl TE: Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc 19:57-61, 1987.
http://d-scholarship.pitt.edu/4158/
76
55Ricordi C, Zeng Y, Alejandro R, Tzakis A, Venkataramanan R, Fung J, Bereiter D, Mintz DH, Starzl TE: In vivo effect of FK506 on human pancreatic islets. Transplantation 52:519-522, 1991.
http://d-scholarship.pitt.edu/4596/
76
56Sun H, Subbotin V, Chen C, Aitouche A, Valdivia LA, Sayegh MH, Linsley PS, Fung JJ, Starzl TE, Rao AS: Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and Anti-CD40 ligand monoclonal antibody. Transplantation 64:1838-1843, 1997.
http://d-scholarship.pitt.edu/5445/
75
57Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, Starzl TE, Meier P, Donner A: The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 183:117-125, 1996.
http://d-scholarship.pitt.edu/5199/
73
58Nalesnik MA, Todo S, Murase N, Gryzan S, Lee PH, Starzl TE: Toxicology of FK 506 in the Lewis rat. Transplant Proc 19:89-92, 1987.
http://d-scholarship.pitt.edu/4160/
72
59Murase N, Kim DG, Todo S, Cramer DV, Fung JJ, Starzl TE: Suppression of allograft rejection with FK 506 I: Prolonged cardiac and liver survival in rats following short course therapy. Transplantation 50:186-189, 1990.
http://d-scholarship.pitt.edu/4486/
72
60Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, McCauley J, Johnston J, Randhawa P, Irish W, Gritsch HA, Naraghi R, Hakala TR, Fung JJ, Starzl TE: A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 67:411-415, 1999.
http://d-scholarship.pitt.edu/5408/
72
61Venkataramanan R, Starzl TE, Yang S, Burckart GJ, Ptachcinski RJ, Shaw BW, Iwatsuki S, Van Thiel DH, Sanghvi A, Seltman H: Biliary excretion of cyclosporine in liver transplant patients. Transplant Proc 17:286-289, 1985.
http://d-scholarship.pitt.edu/3984/
70
62McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE: Pilot trial of FK506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8:1286-1290, 1993.
http://d-scholarship.pitt.edu/5030/
69
63Alessiani M, Cillo U, Fung JJ, Irish W, Abu-Elmagd K, Jain A, Takaya S, Van Thiel D, Starzl TE: Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 25:628-634, 1993.
http://d-scholarship.pitt.edu/4844/
69
64Todo S, Fung JJ, Tzakis A, Demetris AJ, Jain A, Alessiani M, Takaya S, Day R, Gordon R, Starzl TE: One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 23:1397-1402, 1991.
http://d-scholarship.pitt.edu/4562/
66
65Sakr MF, Zetti GM, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS, Starzl TE, Van Thiel DH: FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology 13:947-951, 1991.
http://d-scholarship.pitt.edu/4624/
66
66Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ: A prospective randomized trial of tacrolimus and prednisone vs. tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66:1395-1398, 1998.
http://d-scholarship.pitt.edu/5433/
66
67Starzl TE, Brettschneider L, Penn I, Schmidt RW, Bell P, Kashiwagi N, Townsend CM, Putnam CW: A trial with heterologous antilymphocyte globulin in man. Transplant Proc 1:448-454, 1969.
http://d-scholarship.pitt.edu/3567/
65
68Starzl TE, Hakala TR, Rosenthal JT, Iwatsuki S, Shaw BW Jr: Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids. Surg Gynecol Obstet 154:819-825, 1982.
http://d-scholarship.pitt.edu/3872/
65
69Burckart GJ, Starzl TE, Venkataramanan R, Gartner C Jr, Zitelli B, Malatack J, Urbach A, Ptachcinski R, Shaw BW, Iwatsuki S: Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacology 26:647-651, 1986.
http://d-scholarship.pitt.edu/4030/
65
70Venkataramanan R, Koneru B, Wang CP, Burckart GJ, Caritis SN, Starzl TE: Cyclosporine and its metabolites in mother and baby. Transplantation 46:468-469, 1988.
http://d-scholarship.pitt.edu/4268/
65
71Mazzaferro V, Porter KA, Scotti-Foglieni CL, Venkataramanan R, Makowka L, Rossaro L, Francavilla A, Todo S, Van Thiel DH, Starzl TE: The hepatotropic influence of cyclosporine. Surgery 107:533-539, 1990.
http://d-scholarship.pitt.edu/4445/
62
72Venkataramanan R, Jain A, Cadoff E, Warty V, Krajack A, Imventarza O, Todo S, Fung JJ, Starzl TE: Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 22:52-56, 1990.
http://d-scholarship.pitt.edu/4462/
61
73Hakala TR, Starzl TE, Rosenthal JT, Shaw B, Iwatsuki S: Cadaveric renal transplantation with cyclosporin-A and steroids. Transplant Proc 15:465-470, 1983.
http://d-scholarship.pitt.edu/3891/
60
74Starzl TE, Abu-Elmagd K, Tzakis A, Fung JJ, Porter KA, Todo S: Selected topics on FK 506: With special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs", side effects, mechanisms, and practical pharmacokinetics. Transplant Proc 23:914-919, 1991.
http://d-scholarship.pitt.edu/4545/
60
75Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, Jain A, Selby R, Bronsther O, Marsh W, Ramos H, Reyes J, Gayowski T, Casavilla A, Dodson F, Furukawa H, Marino I, Pinna A, Nour B, Jabbour N, Mazariegos G, McMichael J, Kusne S, Venkataramanan R, Warty V, Murase N, Demetris AJ, Iwatsuki S: Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 220:297-309, 1994.
http://d-scholarship.pitt.edu/5039/
60
76Starzl TE, Putnam CW, Halgrimson CG, Schroter GT, Martineau G, Launois B, Corman JL, Penn I, Booth AS Jr, Groth CG, Porter KA: Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet 133:981-991, 1971.
http://d-scholarship.pitt.edu/3648/
59
77Starzl TE, Halgrimson CG, Penn I, Martineau G, Schroter G, Amemiya H, Putnam CW, Groth CG: Cyclophosphamide and human organ transplantation. Lancet 2:70-74, 1971.
http://d-scholarship.pitt.edu/3643/
58
78Fung JJ, Markus BH, Gordon RD, Esquivel CO, Makowka L, Tzakis A, Starzl TE: Impact of OKT3 in liver transplantation. Transplant Proc 19:37-44, 1987.
http://d-scholarship.pitt.edu/4125/
58
79Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE: The clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 23:1149-1152, 1991.
http://d-scholarship.pitt.edu/4568/
57
80Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, Fung J, Reyes J: Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 70:617-625, 2000.
http://d-scholarship.pitt.edu/5517/
54
81Cadoff E, Venkataramanan R, Krajack A, Jain A, Fung JJ, Todo S, Starzl TE: Assay of FK 506 in plasma. Transplant Proc 22:50-51, 1990.
http://d-scholarship.pitt.edu/4461/
53
82Armitage JM, Kormos RL, Fung J, Starzl TE: The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 23:3054-3057, 1991.
http://d-scholarship.pitt.edu/4638/
53
83Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A, Randhawa P, Smetanka C, Starzl TE, Shapiro R: Living donor renal transplantation using Alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 6:2409-2417, 2006.
http://d-scholarship.pitt.edu/5613/
53
84McCauley J, Takaya S, Fung J, Tzakis A, Abu-Elmagd K, Jain A, Todo S, Starzl TE: The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 23:1444-1447, 1991.
http://d-scholarship.pitt.edu/4570/
52
85Marchioro TL, Axtell HK, LaVia MF, Waddell WR, Starzl TE: The role of adrenocortical steroids in reversing established homograft rejection. Surgery 55:412-417, 1964.
http://d-scholarship.pitt.edu/3452/
51
86Demetris AJ, Fung JJ, Todo S, Banner B, Zerbe T, Sysn G, Starzl TE: Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc 22:25-34, 1990.
http://d-scholarship.pitt.edu/4455/
51
87Zeevi A, Venkataramanan R, Burckart G, Wang P, Murase N, Van Thiel DH, Starzl TE, Makowka L: Sensitivity of activated human lymphocytes to cyclosporine and its metabolites. Hum Immunol 21:143-153, 1988
http://d-scholarship.pitt.edu/4267/
50
88Randhawa PS, Tsamandas AC, Magnone M, Jordan M, Shapiro R, Starzl TE, Demetris AJ: Microvascular changes in renal allografts associated with FK506 (tacrolimus) therapy. Am J Surg Pathol 20:306-312, 1996.
http://d-scholarship.pitt.edu/5256/
50
89Starzl TE, Iwatsuki S, Malatack JJ, Zitelli BJ, Gartner JC Jr, Hakala TR, Rosenthal JT, Shaw BW Jr: Liver and kidney transplantation in children receiving cyclosporin A and steroids. J Pediatr 100:681-686, 1982.
http://d-scholarship.pitt.edu/3873/
49
90Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Gilboa N, Gritsch HA, Irish W, McCauley J, Fung JJ, Hakala TR, Simmons RL, Starzl TE: Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 67:299-303, 1999.
http://d-scholarship.pitt.edu/5424/
49
91Iwatsuki S, Starzl TE, Shaw BW Jr, Yang SL, Zitelli BJ, Gartner JC, Malatack JJ: Long-term use of cyclosporine in liver recipients: Reduction of dosages in the first year to avoid nephrotoxicity. Transplantation 36:641-643, 1983.
http://d-scholarship.pitt.edu/3914/
48
92Jain AB, Fung JJ, Todo S, Alessiani M, Takaya S, Abu-Elmagd K, Tzakis A, Starzl TE: Incidence of treatment of rejection episodes in primary orthotopic liver transplantation under FK506. Transplant Proc 23:928-930, 1991.
http://d-scholarship.pitt.edu/4563/
48
93Jain AB, Fung JJ, Tzakis AG, Venkataramanan R, Abu-Elmagd K, Alessiani M, Reyes J, Irish W, Warty V, Mehta S, Todo S, Starzl TE: Comparative study of cyclosporine and FK 506 dosage requirements in adults and pediatric orthotopic liver transplantation patients. Transplant Proc 23:2763-2766, 1991.
http://d-scholarship.pitt.edu/4659/
48
94McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE: Changes in renal function after liver transplantation under FK 506. Transplant Proc 23:3143-3145, 1991.
http://d-scholarship.pitt.edu/4666/
45
95Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Fung JJ, McCauley J, Randhawa P, Demetris AJ, Irish W, Jain A, Mitchell S, Hakala TR, Simmons RL, Starzl TE: A prospective, randomized trial of FK506/prednisone versus FK506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 27:814-817, 1995.
http://d-scholarship.pitt.edu/5130/
44
96Thomson AW, Carroll PB, McCauley J, Woo J, Abu-Elmagd K, Starzl TE, Van Thiel DH: FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol 14:323-344, 1993.
http://d-scholarship.pitt.edu/3934/
44
97Markus PM, Cai X, Ming W, Demetris AJ, Starzl TE, Fung JJ: Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK 506. Transplantation 52:590-594, 1991.
http://d-scholarship.pitt.edu/4603/
44
98Venkataramanan R, Warty VS, Zemaitis MA, Sanghvi AT, Burckart GJ, Selftman H, Todo S, Makowka L, Starzl TE: Biopharmaceutical aspects of FK-506. Transplant Proc 19:30-35, 1987.
http://d-scholarship.pitt.edu/4182/
43
99Torisu M, Yokoyama T, Amemiya H, Kohler PF, Schroter G, Martineau G, Penn I, Palmer W, Halgrimson CG, Putnam CW, Starzl TE: Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: With particular reference to the Australia antigen. Ann Surg 174:620-639, 1971
http://d-scholarship.pitt.edu/3638/
43
100Tzakis AG, Fung JJ, Todo S, Reyes J, Green M, Starzl TE: Use of FK 506 in pediatric patients. Transplant Proc 23:924-927, 1991.
http://d-scholarship.pitt.edu/4543/
43
101Jordan ML, Shapiro R, Jensen CWB, Scantlebury V, Fung J, Tzakis A, McCauley J, Jain A, Demetris J, Randhawa P, Simmons RL, Hakala TR, Starzl TE: FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 23:3078-3081, 1991.
http://d-scholarship.pitt.edu/4663/
43
102Starzl TE: History of Clinical Transplantation. World J Surg 24:759-782, 2000. (Also published verbatim in: Starzl TE: A History of Clinical Transplantation. In: Surgery: Basic Science and Clinical Evidence. (eds. JA Norton, R Bollinger, AE Chang, SJ Mulvihill, S Lowry, H Pass, R Thompson). Springer Verlag, New York, NY. 2001 and 2008, 1st and 2nd editions).
http://d-scholarship.pitt.edu/5507/
42
103Reyes J, Gayowski T, Fung J, Todo S, Alessiani M, Starzl TE: Expressive dysphasia possibly related to FK 506 in 2 liver transplantation recipients. Transplantation 50:1043-1044, 1990.
http://d-scholarship.pitt.edu/4504/
42
104Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif F, Starzl TE: FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 23:3225-3227, 1991.
http://d-scholarship.pitt.edu/4692/
42
105Tzakis AG, Reyes J, Todo S, Nour B, Shapiro R, Jordan M, McCauley J, Armitage J, Fung JJ, Starzl TE: Two year experience with FK506 in pediatric patients. Transplant Proc 25:619-621, 1993.
http://d-scholarship.pitt.edu/4257/
42
106Sakr MF, McClain CJ, Gavaler JS, Zetti GM, Starzl TE, Van Thiel DH: FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion. J Hepatology 17:301-307, 1993.
http://d-scholarship.pitt.edu/4957/
42
107Anderson DW, Schaefer EJ, Bronzert TJ, Lindgren FT, Forte T, Starzl TE, Niblack GD, Zech LA, Brewer HB Jr: Transport of apolipoproteins A-I and A-II by human thoracic duct lymph. J Clin Invest 67:857-866, 1981.
http://d-scholarship.pitt.edu/3851/
41
108Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Gritsch HA, Ellis D, Gilboa N, Lombardozzi-Lane S, Irish W, Fung JJ, Hakala TR, Simmons RL, Starzl TE: Tacrolimus in pediatric renal transplantation. Transplantation 62:1752-1758, 1996.
http://d-scholarship.pitt.edu/5348/
41
109Jain A, Abu-Elmagd K, Abdallah H, Warty V, Fung J, Todo S, Starzl TE, Venkatarmanan R: Pharmacokinetics of FK 506 in liver transplant recipients after continuos intravenous infusion. J Clin Pharmacol 33:606-611, 1993.
http://d-scholarship.pitt.edu/5033/
41
110Rosenthal JT, Hakala TR, Iwatsuki S, Shaw BW Jr, Starzl TE: Cadaveric renal transplantation under cyclosporine-steroid therapy. Surg Gynecol Obstet 157:309-315, 1983.
http://d-scholarship.pitt.edu/3902/
40
111Burckart GJ, Starzl TE, Venkataramanan R, Hashim H, Wong L, Wang P, Makowka L, Zeevi A, Ptachcinski RJ, Knapp JE, Iwatsuki S, Esquivel C, Sanghvi LA, Van Thiel DH: Excretion of cyclosporine and its metabolites in human bile. Transplant Proc 18:46-49, 1986.
http://d-scholarship.pitt.edu/4072/
40
112Murase N, Kim DG, Todo S, Cramer DV, Fung JJ, Starzl TE: FK 506 suppression of heart and liver allograft rejection II: The induction of graft acceptance in rat. Transplantation 50:739-744, 1990.
http://d-scholarship.pitt.edu/4497/
39
113Tzakis AG, Reyes J, Todo S, Green M, Ohya T, Jain A, Abu-Elmagd K, Alessiani M, Fung JJ, Starzl TE: FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 23:3010-3015, 1991.
http://d-scholarship.pitt.edu/4693/
39
114Francavilla A, Carr BI, Starzl TE, Azzarone A, Carrieri G, Zeng QH: Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology 15:871-877, 1992.
http://d-scholarship.pitt.edu/4731/
39
115Putnam CW, Porter KA, Starzl TE: Hepatic encephalopathy and light electron micrographic changes of the baboon liver after portal diversion. Ann Surg 184:155-161, 1976.
http://d-scholarship.pitt.edu/3749/
38
116Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Hakala TR, Fung JJ, Simmons RL, Starzl TE, Shapiro R: Outcome after steriod withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 70:760-764, 2000.
http://d-scholarship.pitt.edu/5537/
38
117Starzl TE: Current concepts: Heterologous antilymphocyte globulin. N Engl J Med 279:700-703, 1968.
http://d-scholarship.pitt.edu/3558/
35
118Fung JJ, Todo S, Tzakis A, Alessiani M, Abu-Elmagd K, Jain A, Bronsther O, Martin M, Gordon R, Starzl TE: Current status of FK 506 in liver transplantation. Transplant Proc 23:1902-1905, 1991.
http://d-scholarship.pitt.edu/4609/
35
119Lee K, Stangl MJ, Todo S, Langrehr JM, Starzl TE, Schraut WH: Successful orthotopic small bowel transplantation with short term FK 506 immunosuppressive therapy. Transplant Proc 22:78-79, 1990.
http://d-scholarship.pitt.edu/4468/
35
120Fung JJ, Demetris AJ, Porter KA, Iwatsuki S, Gordon RD, Esquivel C, Jaffe R, Shaw BW Jr, Starzl TE: Use of OKT3 with cyclosporine and steroids for reversal of acute kidney and liver allograft rejection. Nephron 46:19-33, 1987.
http://d-scholarship.pitt.edu/4087/
34
121Tze WJ, Tai J, Murase N, Tzakis A, Starzl TE: Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 23:3158-3160, 1991.
http://d-scholarship.pitt.edu/4694/
34
122Jordan ML, Shapiro R, Vivas CA, Scantlebury VP, Darras FS, Carrieri G, McCauley J, Demetris AJ, Randhawa P, Jensen C, Hakala TR, Fung J, Starzl TE: FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 25:638-640, 1993.
http://d-scholarship.pitt.edu/4857/
34
123Todo S, Porter KA, Kam I, Lynch S, Venkataramanan R, DeWolf A, Starzl TE: Canine liver transplantation under Nva2 Cyclosporine versus cyclosporine. Transplantation 41:296 300, 1986.
http://d-scholarship.pitt.edu/4049/
33
124Gordon RD, Tzakis AG, Iwatsuki S, Todo S, Esquivel CO, Marsh JW, Stieber A, Makowka L, Starzl TE: Experience with orthoclone OKT3 monoclonal antibody in liver transplantation. Am J Kidney Dis 11:141-144, 1988.
http://d-scholarship.pitt.edu/4226/
33
125Todo S, Murase N, Ueda Y, Podesta L, ChapChap P, Kahn D Okuka K, Imventarza O, Casavilla A, Demetris J, Makowka L, Starzl TE: Effect of FK506 in experimental organ transplantation. Transplant Proc 20:215-219, 1988.
http://d-scholarship.pitt.edu/4228/
33
126Wang CP, Burckart GJ, Ptachcinski RJ, Venkataramanan R, Schwinghammer T, Hakala T, Griffith B, Hardesty R, Shadduck R, Knapp J, Van Thiel DH, Makowka L, Starzl TE: Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc 20:591-596, 1988.
http://d-scholarship.pitt.edu/4238/
33
127Van Thiel D, Igbal M, Jain A, Fung J, Todo S, Starzl TE: Gastrointestinal and metabolic problems associated with immunosuppression with either cyclosporine or FK 506 in liver transplantation. Transplant Proc 22:37-40, 1990.
http://d-scholarship.pitt.edu/4457/
33
128Warty VS, Venkataramanan R, Zendehrouh P, Mehta S, McKaveney T, Flowers J, Zuckerman S, Krajak A, Zeevi A, Fung J, Todo S, Starzl TE: Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc 23:2730-2731, 1991.
http://d-scholarship.pitt.edu/4700/
33
129Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, Vats AN, Khan AS, Gray EA, Zeevi A, McFeaters C, James G, Grosso MJ, Marcos A, Starzl TE: Antilymphoid antibody preconditioning with tacrolimus monotherapy for pediatric renal transplantation. J Pediatr 148:813-818, 2006.
http://d-scholarship.pitt.edu/5604/
33
130Starzl TE, Fung JJ: Orthoclone OKT3 in treatment of allografts rejected under cyclosporine-steroid therapy. Transplant Proc 4:937-941, 1986.
http://d-scholarship.pitt.edu/4057/
32
131Jain A, Demetris A, Kashyap R, Blakomer K, Ruppert K, Rohal S, Starzl TE, Fung J: Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean followup of 6 years. Liver Transplantation 7:623-630, 2001.
http://d-scholarship.pitt.edu/5548/
32
132Zeevi A, Eiras G, Burckert G, Makowka L, Venkataramanan R, Wang CP, Van Thiel DH, Murase N, Starzl TE, Duquesnoy R: Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplants Proc 20:115-121, 1988.
http://d-scholarship.pitt.edu/4290/
31
133Nalesnick M, Lai HS, Murase N, Todo S, Starzl TE: The effect of FK 506 and cyclosporine A on the Lewis rat renal ischemia model. Transplant Proc 22:87-89, 1990.
http://d-scholarship.pitt.edu/4470/
31
134Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE: Weaning of immunosuppression in long-term recipients of living related renal transplants: A preliminary study. Transplant Proc 27:207-209, 1995.
http://d-scholarship.pitt.edu/5125/
31
135Mieles L, Gordon RD, Mintz D, Toussaint RM, Imventarza O, Starzl TE: Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc 23:949-953, 1991.
http://d-scholarship.pitt.edu/4557/
30
136Armitage JM, Kormos RL, Griffith BP, Hardesty RL, Fricker FJ, Stuart RS, Marrone GC, Todo S, Fung J, Starzl TE: The clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc 23:1149-1152, 1991.
http://d-scholarship.pitt.edu/4568/
30
137Jain AB, Fung JJ, Todo S, Reyes J, Selby R, Irish W, Doyle H, Abu-Elmagd K, Casavilla A, Nour B, Bronsther O, Jabbour N, Pinna A, Dodson F, Ramos H, McMichael JJ, McCauley J, Tzakis AG, Marino I, Marsh W, Venkataramanan R, Iwatsuki S, Starzl TE: One thousand consecutive primary orthotopic liver transplants under FK506: survival and adverse events. Transplant Proc 27:1099-1104, 1995.
http://d-scholarship.pitt.edu/5121/
30
138Shapiro R, Vivas C, Scantlebury VP, Jordan ML, Gritsch HA, Neugarten J, McCauley J, Randhawa P, Irish W, Fung JJ, Hakala T, Simmons RL, Starzl TE: “Suboptimal” kidney donors -- the experience with tacrolimus-based immunosuppression. Transplantation 62:1242-1246, 1996.
http://d-scholarship.pitt.edu/5263/
30
139Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, Starzl TE, Fung JJ: A Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 72:1091-1097, 2001.
http://d-scholarship.pitt.edu/5538/
30
140Starzl TE: Immunosuppressive Therapy and Tolerance of Organ Allografts. New Engl J Med 358: 407-411, 2008.
http://d-scholarship.pitt.edu/5630/
30
141Mieles L, Todo S, Fung JJ, Jain A, Furukawa H, Susuki M, Starzl TE: Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc 22:41-43, 1990.
http://d-scholarship.pitt.edu/4458/
29
142Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE: Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 52:1086-1087, 1991.
http://d-scholarship.pitt.edu/4614/
29
143Rilo HLR, Zeng Y, Alejandro R, Carroll PB, Bereiter D, Venkataramanan R, Tzakis AG, Starzl TE, Ricordi C: Effect of FK 506 on function of human islets of Langerhans. Transplant Proc 23:3164-3165, 1991.
http://d-scholarship.pitt.edu/4680/
29
144Starzl TE, Koep LJ, Weil R III, Halgrimson CG, Franks JJ: Thoracic duct drainage in organ transplantation: Will it permit better immunosuppression? Transplant Proc 11:276-284, 1979.
http://d-scholarship.pitt.edu/3803/
28
145Ericzon GB, Todo S, Lynch S, Kam I, Ptachcinski RJ, Burckart GJ, Van Thiel DH, Starzl TE, Venkataramanan R: Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc 19:1248 1249, 1987.
http://d-scholarship.pitt.edu/4118/
28
146Venkataramanan R, Wang CP, Habucky K, Ptachinski RJ, Burckart GJ, Koneru B, Baker R, Todo S, Starzl TE: Species-specific cyclosporine metabolism. Transplant Proc 20:680 683, 1988.
http://d-scholarship.pitt.edu/4237/
28
147Zeevi A, Eiras G, Burckart G, Jain A, Kragack A, Venkataramanan R, Todo S, Fung J, Starzl TE, Duquesnoy RJ: Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. Transplant Proc 22:60-63, 1990.
http://d-scholarship.pitt.edu/4464/
27
148Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE: FK 506 reverses acute graft-versus-host disease following allogeneic bone marrow transplantation in rats. Surgery 110:357-364, 1991.
http://d-scholarship.pitt.edu/4592/
27
149Starzl TE: Debate: FK506 vs cyclosporine. Transplant Proc 25:511-512, 1993.
http://d-scholarship.pitt.edu/4865/
27
150Shapiro R, Jordan M, Scantlebury V, Vivas C, Fung JJ, McCauley J, Tzakis A, Irish W, Mitchell S, Jensen C, Jain A, Hakala T, Simmons RL, Starzl TE: A prospective, randomized trial of FK506 in renal transplantation - a comparison between double and triple drug therapy. Clin Transplant 8:508-515, 1994.
http://d-scholarship.pitt.edu/5173/
27
151Abu-Elmagd K, Fung J, McGhee W, Martin D, Mazariegos G, Schaefer N, Demetris J, Starzl TE, Reyes J: The efficacy of daclizumab for intestinal transplantation: Preliminary report. Transplant Proc 32:1195-1196, 2000.
http://d-scholarship.pitt.edu/5519/
26
152Starzl TE, Weil R III, Koep LJ, Iwaki Y, Terasaki PI, Schroter GPJ: Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet 149:815-821, 1979.
http://d-scholarship.pitt.edu/3818/
25
153Esquivel CO, Fung JJ, Markus B, Iwatsuki S, Gordon RD, Makowka L, Marsh JW Jr, Tzakis AG, Todo S, Starzl TE: OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc 19:2443 2446, 1987.
http://d-scholarship.pitt.edu/4111/
25
154Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE: FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 23:3171-3172, 1991.
http://d-scholarship.pitt.edu/4642/
25
155Tauxe WN, Mochizuki T, McCauley J, Starzl TE, Jain A, Charron M: A comparison of the renal effects (ERPF, GFR and FF) of FK 506 and cyclosporine in patients with liver transplantation. Transplant Proc 23:3146-3147, 1991.
http://d-scholarship.pitt.edu/4688/
25
156Todo S, Murase N, Kahn D, Pan CE, Okuda K, Cemaj S, Casavilla A, Mazzaferro V, Ghalab A, Rhoe BS, Yang M, Taniguchi K, Nalesnik M, Makowka L, Starzl TE: Effect of 15-Deoxyspergualin on experimental organ transplantation. Transplant Proc 20:233-236, 1988.
http://d-scholarship.pitt.edu/4230/
25
157Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A, Randhawa P, Smetanka C, Starzl TE, Shapiro R: Living donor renal transplantation using Alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 6:2409-2417, 2006.
http://d-scholarship.pitt.edu/5613/
24
158Sanghvi A, Warty V, Zeevi A, Diven W, Duquesnoy R, Makowka L, Starzl TE: FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes. Transplant Proc 19:45-49, 1987.
http://d-scholarship.pitt.edu/4165/
24
159Ono K, Blanchard H, Kashiwagi N, MacSween RNM, Claman HN, Starzl TE: Effects of phytohemagglutinin on humoral antibody response, delayed hypersensitivity, and homograft rejection. Surgery 67:322-327, 1970.
http://d-scholarship.pitt.edu/3576/
23
160Starzl TE, Penn I, Breetschneider L, Ono K, Kashiwagi N: Selected topics on antilymphocyte serum. Fed Proc 29:186-190, 1970.
http://d-scholarship.pitt.edu/3584/
23
161Gordon RD, Iwatsuki S, Shaw BW Jr, Starzl TE: Cyclosporine-steroid combination therapy in 84 cadaveric renal transplants. Am J Kidney Dis 5:307-312, 1985.
http://d-scholarship.pitt.edu/4000/
23
162Abu-Elmagd KM, Fung JJ, Alessiani M, Jain A, Takaya S, Venkataramanan R, Warty VS, Shannon W, Todo S, Tzakis A, Van Thiel D, Starzl TE: Strategy of FK 506 therapy in liver transplant patients: Effect of graft function. Transplant Proc 23:2771-2774, 1991.
http://d-scholarship.pitt.edu/4634/
23
163Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, McCauley J, McQuitty D, Randhawa P, Irish W, McMichael J, Hakala TR, Simmons RL, Fung JJ, Starzl TE: Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 30:1375-1377, 1998.
http://d-scholarship.pitt.edu/5422/
23
164Starzl TE: Clinical aspects of cyclosporine therapy: A summation. Transplant Proc 15:3103-3107, 1983.
http://d-scholarship.pitt.edu/3913/
22
165Shapiro R, Jordan ML, Scantlebury VP, Fung JJ, Jensen C, Vivas C, McCauley J, Irish WD, Mitchell S, Demetris AJ, Randhawa P, Jain A, Tzakis A, Hakala TR, Simmons RL, Starzl TE: Randomized trial of FK506/prednisone versus FK506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc 25:669-672, 1993.
http://d-scholarship.pitt.edu/4842/
22
166Fung JJ, Starzl TE: FK506 in solid organ transplantation. Ther Drug Monit 17(6):592-595, 1995.
http://d-scholarship.pitt.edu/5202/
22
167Singh N, Mieles L, Yu VL, Starzl TE: Decreased incidence of viral infections in liver transplant recipients. Possible effects of FK506? Dig Dis Sci 49:15-18, 1994.
http://d-scholarship.pitt.edu/5037/
22
168Eghtesad B, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, Gray EA, Shakil O, Marcos A, Starzl TE: Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transplant 11:1343-1352, 2005.
http://d-scholarship.pitt.edu/5600/
22
169Zeevi A, Woan M, Yao G-Z, Venkataramanan R, Todo S, Starzl TE, Duquesnoy RJ: Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. Transplant Proc 23:2928-2930, 1991.
http://d-scholarship.pitt.edu/4706/
21
170Shapiro R, Zeevi A, Basu A, Tan HP, Kayler LK, Blisard DM, Thai NL, Girnita AL, Randhawa PS, Gray EA, Marcos A, Starzl TE: Alemtuzumab preconditioning with tacrolimus monotherapy - The impact of serial monitoring for donor-specific antibody. Transplantation 85:1125-1132, 2008.
http://d-scholarship.pitt.edu/5629/
21
171Starzl TE, Groth CG, Putnam CW, Corman J, Halgrimson CG, Penn I, Husberg B, Gustafsson A, Cascardo S, Geis P, Iwatsuki S: Cyclophosphamide for clinical renal and hepatic transplantation. Transplant Proc 5:511-516, 1973.
http://d-scholarship.pitt.edu/3684/
20
172Venkataramanan R, Yang S, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE: Diurnal variation in cyclosporine kinetics. Therapeutic Drug Monitoring 8:380-381, 1986.
http://d-scholarship.pitt.edu/4051/
20
173Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE: FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 23:3005-3006, 1991.
http://d-scholarship.pitt.edu/4647/
20
174Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, Casavilla FA, McCauley J, Johnston JR, Randhawa P, Irish W, Hakala TR, Fung JJ, Starzl TE: A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplanstation: first report. J Urology 160:1982-1986, 1998.
http://d-scholarship.pitt.edu/5448/
20
175Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, Vats AN, Kayler, Erkan E, McFeaters CG, James G, Gross MJ, Zeevi A, Gray EA, Marcos A, Starzl TE: Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant 7:2736-2738, 2007.
http://d-scholarship.pitt.edu/5616/
20
176Zeevi A, Duquesnoy R, Eiras G, Rabinowich H, Todo S, Makowka L, Starzl TE: In Vitro immunosuppressive effects of FK 506 in combination with other drugs. Transplant Proc 20:220-222, 1988.
http://d-scholarship.pitt.edu/4212/
19
177Todo S, Tzakis A, Reyes J, Abu-Elmagd K, Casavilla A, Fung JJ, Starzl TE: Intestinal transplantation in humans under FK506. Transplant Proc 25:1198-1199, 1993.
http://d-scholarship.pitt.edu/4849/
19
178Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, McCauley J, Ellis D, Gilboa N, Lombardozzi-Lane S, Randhawa P, Demetris AJ, Irish W, Hakala TR, Simmons RL, Fung JJ, Starzl TE: Tacrolimus in renal transplantation. Transplant Proc 28:2117-2118, 1996.
http://d-scholarship.pitt.edu/5242/
19
179Wang CP, Hartman NR, Venkataramanan R, Jardine I, Lin FT, Knapp VE, Starzl TE, Burckart GJ: Isolation of ten cyclosporine metabolites from human bile. Drug Metab Disp 17:292-296, 1989.
http://d-scholarship.pitt.edu/4414/
18
180D'Mello A, Venkataramanan R, Satake M, Todo S, Takaya S, Ptachcinski RJ, Burckart GJ, Starzl TE: Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 64:441-454, 1989.
http://d-scholarship.pitt.edu/4413/
18
181Jain A, Fung JJ, Venkataramanan R, Todo S, Alessiani M, Starzl TE: FK 506 dosage in human organ transplantation. Transplant Proc 22:23-24, 1990.
http://d-scholarship.pitt.edu/4454/
18
182McCauley J, Fung JJ, Brown H, Deballi P, Jain A, Todo S, Starzl TE: Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc 23:3148-3149, 1991.
http://d-scholarship.pitt.edu/4668/
18
183Jensen CWB, Jordan ML, Schneck FX, Shapiro R, Tzakis A, Hakala TR, Starzl TE: Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 23:3075-3077, 1991.
http://d-scholarship.pitt.edu/4662/
18
184Tanabe M, Todo S, Murase N, Irish W, Miyazawa H, Fujisaki S, Starzl TE: Combined immunosuppressive therapy with low-dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplantation 58:23-27, 1994.
http://d-scholarship.pitt.edu/5031/
18
185Gordon RD, Todo S, Tzakis AG, Fung JJ, Stieber A, Staschak SM, Iwatsuki S, Starzl TE: Liver transplantation under cyclosporine: A decade of experience. Transplant Proc 23:1393-1396, 1991.
http://d-scholarship.pitt.edu/4572/
17
186Starzl TE: Introduction: The drug with no name. Transplant Proc 23:2709, 1991.
http://d-scholarship.pitt.edu/4684/
17
187Wu GD, Cramer DV, Chapman FA, Cajulis E, Wang HK, Starzl TE, Makowka L: FK 506 inhibits the development of transplant arteriosclerosis. Transplant Proc 23:3272-3274, 1991.
http://d-scholarship.pitt.edu/4702/
17
188Cooper MH, Gregory SH, Starzl TE, Wing EJ: Rapamycin but not FK506 inhibits the proliferation of bone marrow-derived mononuclear phagocytes induced by colony-stimulating factors. Transplantation 57:433-439, 1994.
http://d-scholarship.pitt.edu/4984/
17
189Popovtzer MM, Pinggera WF, Robinette J, Holmes JH, Halgrimson CG, Starzl TE: Acute renal response to large doses of intravenous prednisolone in kidney homograft recipients and in normal subjects. J Lab Clin Med 78:39-52, 1971.
http://d-scholarship.pitt.edu/3629/
16
190Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Thiel DH: The clearance of cyclosporine by hemodialysis. J Clin Pharmacol 24:528-531, 1984.
http://d-scholarship.pitt.edu/3950/
16
191Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang S, Starzl TE: Extraction ratio of cyclosporine in a liver transplant patient. J Pharm Sci 74:901-902, 1985.
http://d-scholarship.pitt.edu/3997/
16
192 Burckart GJ, Venkataramanan R, Ptachcinski RJ, Starzl TE, Griffith BP, Hakala TR, Rosenthal JT, Hardesty RL, Iwatsuki S, Brady J, Van Thiel DH: Cyclosporine pharmakokinetic profiles in liver, heart, and kidney transplant patients as determined HPLC. Transplant Proc 18:129-136, 1986.
http://d-scholarship.pitt.edu/4073/
16
193Hashem H, Venkataramanan R, Burckart GJ, Makowka L, Starzl TE, Fu E, Wong LK: Identification of the aldehydic metabolites. Transplant Proc 20:176-178, 1988.
http://d-scholarship.pitt.edu/4254/
16
194Hoffman A, Makowka L, Cai X, Cramer DV, Pascualone A, Todo S, Starzl TE: The effect of FK 506 on small intestine allotransplantation in the rat. Transplant Proc 22:76-77, 1990.
http://d-scholarship.pitt.edu/4467/
16
195Cooper MH, Hartman GG, Starzl TE, Fung JJ: The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transplant Proc 23:3234-3235, 1991.
http://d-scholarship.pitt.edu/4644/
16
196Staschak S, Wagner S, Block G, Van Thiel D, Jain A, Fung JJ, Todo S, Starzl TE: A cost comparison of liver transplantation with FK 506 or cyclosporine as the primary immunosuppressive agent. Transplant Proc 22:47-49, 1990.
http://d-scholarship.pitt.edu/4460/
15
197Groth CG, Brent LB, Calne RY, Dausset JB, Good RA, Murray JE, Shumway NE, Schwartz RS, Starzl TE, Terasaki PI, Thomas ED, van Rood JJ: Historical landmarks in clinical transplantation: conclusions from the concensus conference at the University of California, Los Angeles (UCLA). World J Surg 24:834-843, 2000.
http://d-scholarship.pitt.edu/5497/
14
198Venkataramanan R, DilizPerez H, Schwinghammer T, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE: Effect of bile on cyclosporine absorption in dogs. Research communications in Chemical and Pharmacology 53:137-140, 1986
http://d-scholarship.pitt.edu/4053/
14
199Burckart GJ, Jain A, Diven W, Venkataramanan R, Starzl TE: Cyclosporine measurement by FPIA, PC-RIA, and HPLC following liver transplantation. Transplant Proc 22:1319-1322, 1990.
http://d-scholarship.pitt.edu/4507/
14
200Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE: Long-term insulin requirement after liver transplantation with FK 506 in American Veterans. Transplant Proc 25:677-678, 1993.
http://d-scholarship.pitt.edu/4856/
14
201Amemiya H, Yokoyama T, Putnam CW, Torisu M, Starzl TE: The nature of antiplatelet activity in antilymphoblast ALG: With special reference to cross-reacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients. Clin Exp Immunol 10:417-426, 1972.
http://d-scholarship.pitt.edu/3645/
13
202Takaya S, Zaghloul I, Iwatsuki S, Starzl TE, Noguchi T, Ohmori Y, Burckart GJ, Ptachcinski RJ, Venkataramanan R: Effect of liver dysfunction on cyclosporine pharmacokinetics. Transplant Proc 19:1246-1247, 1987
http://d-scholarship.pitt.edu/4119/
13
203Wang CP, Burckart GJ, Venkataramanan R, Ptachcinski RJ, Cuellar RE, Makowka L, Van Thiel DH, Starzl TE: Cyclosporine metabolite profiles in the blood of liver transplant patients. Transplant Proc 20:173-175, 1988.
http://d-scholarship.pitt.edu/4222/
13
204McMichael J, Irish W, McCauley J, Shapiro R, Gordon R, Van Thiel DH, Lieberman R, Warty VS, Fung J, Starzl TE: Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. Transplant Proc 23:2780-2782, 1991.
http://d-scholarship.pitt.edu/4670/
13
205Odocha O, McCauley J, Scantlebury V, Shapiro R, Carroll P, Jordan M, Vivas C, Fung JJ, Starzl TE: Posttransplnt diabetes mellitus in African Americans after renal transplantation under FK506 immunosuppression. Transplant Proc 25:2433-2434, 1993.
http://d-scholarship.pitt.edu/5012/
13
206Starzl TE, Marchioro TL, Iwasaki Y: Attributes of clinically used immunosuppressive drugs: Possible future use of antilymphoid sera. Fed Proc 26:944-952, 1967.
http://d-scholarship.pitt.edu/3520/
12
207Kashiwagi N, Groth CG, Amend JR, Gecelter L, Blanchard H, Starzl TE: Improvements in the preparation of heterologous antilymphocyte globulin with special reference to absorption and diethylaminoethyl cellulose batch production. Surgery 65:477-484, 1969.
http://d-scholarship.pitt.edu/3555/
12
208Starzl TE, Putnam CW, Halgrimson CG, Groth CG, Booth AS Jr, Penn I: Renal transplantation under cyclophosphamide. Transplant Proc 4:461-464, 1972.
http://d-scholarship.pitt.edu/3670/
12
209Putnam CW, Halgrimson CG, Groth CG, Kashiwagi N, Porter KA, Starzl TE: Immunosuppression with cyclophosphamide in the dog. Clin Exp Immunol 22:323-329, 1975.
http://d-scholarship.pitt.edu/3736/
12
210Starzl TE, Klintmalm GBG, Iwatsuki S, Schroter G, Weil R III: Late follow-up after thoracic duct drainage in cadaveric renal transplantation. Surg Gynecol Obstet 153:377-382, 1981.
http://d-scholarship.pitt.edu/3854/
12
211Makowka L, Chapman F, Qian S, Zerbe A, Lee P-H, Saunders R, Todo S, Starzl TE: The effect of FK 506 on hyperacute rejection in presensitized rats. Transplant Proc 19:79-83, 1987.
http://d-scholarship.pitt.edu/4161/
12
212Burckart GJ, Wang CP, Zeevi A, Venkataramanan R, Ptachcinski RJ, Hashem H, Wong L, Makowka L, Starzl TE: Cyclosporine metabolites in human bile: Recovery and immunologic activity. Transplant Proc 20:190-192, 1988.
http://d-scholarship.pitt.edu/4221/
12
213Starzl TE: New approaches in the use of cyclosporine with particular reference to the liver. Transplant Proc 20:356-360, 1988.
http://d-scholarship.pitt.edu/4232/
12
214Starzl TE: Contempo 89: Transplantation. JAMA 261:2894-2895, 1989.
http://d-scholarship.pitt.edu/4349/
12
215Furukawa H, Imventarza O, Venkataramanan R, Suzuki M, Zhu Y, Warty VS, Fung J, Todo S, Starzl TE: The effect of bile duct ligation and bile diversion on FK 506 pharmacokinetics in dogs. Transplantation 53:722-725, 1992.
http://d-scholarship.pitt.edu/4716/
12
216Jain A, Venkataramanan R, Todo S, Abu-Elmagd K, Fung J, Warty V, Tzakis A, Reyes J, Alessiani M, Starzl TE: Intravenous, oral pharmacokinetics and oral dosing of FK 506 in small bowel transplant patients. Transplant Proc 24:1181-1182, 1992.
http://d-scholarship.pitt.edu/4734/
12
217Jordan ML, Naraghi R, Shapiro R, Smith D, Vivas CA, Scantlebury VP, Gritsch HA, McCauley J, Randhawa P, Demetris AJ, McMichael J, Fung JJ, Starzl TE: Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc 30:1257-1260, 1998.
http://d-scholarship.pitt.edu/5428/
12
218Burckart GJ, Ptachcinski RJ, Venkataramanan R, Iwatsuki S, Esquivel C, Van Thiel DH, Starzl TE: Cyclosporine through concentration monitoring in liver transplant patients. Transplant Proc 18:188-193, 1986.
http://d-scholarship.pitt.edu/4071/
11
219Markus BH, Fung JJ, Gordon RD, Iwatsuki S, Esquivel CO, Makowka L, Starzl TE: Effect of OKT3 on survival and rate of retransplantation. Transplant Proc 19(Suppl.3):61-62, 1987.
http://d-scholarship.pitt.edu/4085/
11
220Gordon RD, Fung JJ, Iwatsuki S, Duquesnoy RJ, Starzl TE: Immunological factors influencing liver graft survival. Gastroenterol Clinics North Am 17:53-69, 1988.
http://d-scholarship.pitt.edu/4280/
11
221Starzl TE: FK-506 a potential breakthrough in immunosuppression: Summing up. Transplant Proc 19:103, 1987.
http://d-scholarship.pitt.edu/4169/
11
222Sakr MF, Zetti GM, Farghali H, Hassanein TH, Gavaler JS, Starzl TE, Van Thiel DH: Protective effect of FK 506 against hepatic ischemia in rats. Transplant Proc 23:340-341, 1991.
http://d-scholarship.pitt.edu/4560/
11
223Steeves M, Abdallah HY, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Abu-Elmagd K, Jain AK, Fung J, Todo S, Starzl TE: In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. J Pharm Pharmacol 43:574-577, 1991.
http://d-scholarship.pitt.edu/4618/
11
224Abu-Elmagd KM, Fung J, Draviam R, Shannon W, Jain A, Alessiani M, Takaya S, Venkataramanan R, Warty VS, Tzakis A, Todo S, Starzl TE: Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc 23:2767-2770, 1991.
http://d-scholarship.pitt.edu/4633/
11
225Lemster B, Woo J, Strednak J, Wang SC, Todo S, Starzl TE, Thomson AW: Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid or brequinar sodium. Transplant Proc 24:2845-2846, 1992.
http://d-scholarship.pitt.edu/4832/
10
226Putnam CW, Kashiwagi N, Iwasaki Y, Terasaki PI, Marchioro TL, Starzl TE: Interspecies reactivity and intraspecies specificity of antilymphoid globulin. Surgery 61:951-954, 1967.
http://d-scholarship.pitt.edu/3516/
9
227Starzl TE, Groth CG, Kashiwagi N, Putnam CW, Corman JL, Halgrimson CG, Penn I: Clinical experience with horse antihuman ALG. Transplant Proc 4:491-495, 1972.
http://d-scholarship.pitt.edu/3671/
9
228Liebert M, Rosenthal JT, Merrall E, Taylor RJ, Singh G, Starzl TE, Rabin BS, Hakala TR: Peripheral blood T lymphocytes found in renal allograft recipients treated with cyclosporine. Transplantation 36:200-202, 1983.
http://d-scholarship.pitt.edu/3919/
9
229Zitelli BJ, Gartner JC Jr, Malatack JJ, Shaw BW Jr, Iwatsuki S, Starzl TE: Hepatic homograft survival in pediatric orthotopic liver transplantation with cyclosporine and steroids. Transplant Proc 15:2592-2596, 1983.
http://d-scholarship.pitt.edu/3917/
9
230Taylor RJ, Landreneau MD, Makowka L, Rosenthal TJ, Gordon RD, Tzakis AG, Starzl TE, Hakala TR: Cyclosporine immunosuppression and delayed graft function in 455 cadaveric renal transplants. Transplant Proc 19:2100-2103, 1987.
http://d-scholarship.pitt.edu/4131/
9
231Venkataramanan R, Todo S, Zaghloul I, Lynch S, Kam I, Ptachcinski RJ, Burckart GJ, Starzl TE: Comparative pharmacokinetics of cyclosporine and NVa2 cyclosporine in dogs. Transplant Proc 19:1265 1266, 1987.
http://d-scholarship.pitt.edu/4116/
9
232Fung JJ, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Jordan M, Armitage J, Jain A, Martin M, Bronsther O, Stieber A, Kormos R, Selby R, Gordon R, Starzl TE: FK 506 in clinical organ transplantation. Clin Transplant 5:517-522, 1991.
http://d-scholarship.pitt.edu/4708/
9
233Felser I, Wagner S, Depee J, Johnson N, Staschak S, Jain A, Fung JJ, Starzl TE: Changes in quality of life following conversion from CyA to FK506 in orthotopic liver transplant patients. Transplant Proc 23:3032-3034, 1991.
http://d-scholarship.pitt.edu/4653/
9
234Takaya S, Bronsther O, Abu-Elmagd K, Ramos H, Fung JJ, Todo S, Starzl TE: Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK506. Transplant Proc 25:2381-2385, 1993.
http://d-scholarship.pitt.edu/4794/
9
235Subbotin V, Sun H, Chen C, Aitouche A, Valdivia L, Fung JJ, Starzl TE, Rao AS: Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc 30:941-942, 1998.
http://d-scholarship.pitt.edu/5430/
9
236Cooper MH, Markus PM, Cai X, Starzl TE, Fung JJ: Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. Transplant Proc 23:3238-3239, 1991.
http://d-scholarship.pitt.edu/4645/
8
237Farghali H, Gasbarrini A, Borle AB, Nalesnik MA, Francavilla A, Fagiuoli S, Starzl TE, Van Thiel DH: FK 506 modulates D-galactosamine-induced hepatitis in rats. Transplant Proc 23:2809-2811, 1991.
http://d-scholarship.pitt.edu/4651/
8
238Rao P, Sun H, Snyder J, Fung JJ, Starzl TE: Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc 23:2873-2874, 1991.
http://d-scholarship.pitt.edu/4677/
8
239Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE: Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 52:1086-1087, 1991.
http://d-scholarship.pitt.edu/4614/
8
240McMichael J, Lieberman R, Doyle H, McCauley J, Fung J, Starzl TE: An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol 33:599-605, 1993.
http://d-scholarship.pitt.edu/4983/
8
241Ellis D, Shapiro R, Moritz M, Vats A, Basu A, Tan H, Kayler L, Janosky J, Starzl TE: Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. Transplantation83:1563-1570, 2007.
http://d-scholarship.pitt.edu/5626/
8
242Kashiwagi N, Sherer D, Townsend CM, Jacobs R, Ono K, Kapur B, Starzl TE: Antibody localization in horse, rabbit, and goat antilymphocyte sera. Surgery 67:789-798, 1970.
http://d-scholarship.pitt.edu/3582/
7
243Ono K, Blanchard H, Kashiwagi N, MacSween RNM, Claman HN, Starzl TE: Effects of phytohemagglutinin on humoral antibody response, delayed hypersensitivity, and homograft rejection. Surgery 67:322-327, 1970.
http://d-scholarship.pitt.edu/3576/
7
244Gordon RD, Starzl TE, Fung JJ, Iwatsuki S, Esquivel CO, Tzakis A, Todo S: Monoclonal antibody therapy with ciclosporin and steroids in nonmatched cadaveric renal transplants. Nephron 46(Suppl.1):56 59, 1987.
http://d-scholarship.pitt.edu/4129/
7
245Starzl TE: FK-506 a potential breakthrough in immunosuppression: Summing up. Transplant Proc 19:103, 1987.
http://d-scholarship.pitt.edu/4169/
7
246Takaya S, Iwatsuki S, Noguchi T, Koie H, Zaghloul I, Venkataramanan R, Starzl TE: The influence of liver dysfunction on cyclosporine pharmacokinetics - a comparison between 70 percent hepatectomy and complete bile duct ligation in dogs. Japanese J Surg 19(No.1):49-56, 1989
http://d-scholarship.pitt.edu/4402/
7
247Markus PM, Cai X, Selvaggi G, Cooper M, Harnaha J, Fung JJ, Starzl TE: The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc 23:3232-3233, 1991.
http://d-scholarship.pitt.edu/4665/
7
248Mieles LA, Fung JJ, Yokoyama I, McCauley J, Singh N, Todo S, Gordon RD, Starzl TE: Liver transplantation of American veterans under FK 506 immunosuppression: A preliminary report. Transplant Proc 23:3016-3018, 1991.
http://d-scholarship.pitt.edu/4671/
7
249Fung JJ, Thomson AW, Pinna A, Selby RR, Starzl TE: State of immunosuppressive agents in organ transplantation. Transplant Proc 24:2372-2374, 1992.
http://d-scholarship.pitt.edu/4898/
7
250Zeevi A, Yao GZ, Venkataramanan R, Duquesnoy RJ, Todo S, Fung JJ, Starzl TE: Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc 25:781-783, 1993.
http://d-scholarship.pitt.edu/4851/
7
251Ikoma A, Nakada K, Suzuki T, Reynolds JC, Todo S, Starzl TE: Effect of FK 506 on gastrointestinal tract: Comparison with erythromycin. Gastroenterology 104:A525, 1993.
http://d-scholarship.pitt.edu/4971/
7
252Tai J, Tze WJ, Murase N, Tzakis A, Starzl TE: In vivo and in vitro effect of FK 506 on rat leydig cell function. Transplant Proc 23:3202-3204, 1991.
http://d-scholarship.pitt.edu/4686/
7
253Tanabe M, Todo S, Murase N, Irish W, Miyazawa H, Fujisaki S, Starzl TE: Therapeutic synergism between low-dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplant Proc 27:364-365, 1995.
http://d-scholarship.pitt.edu/5134/
7
254Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Gritsch HA, McCauley J, McQuitty D, Randhawa P, Irish W, McMichael J, Hakala TR, Simmons RL, Fung JJ, Starzl TE: Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 30:1375-1377, 1998.
http://d-scholarship.pitt.edu/5422/
7
255McCauley J, Shapiro R, Woods H, Scantlebury V, Irish W, McMichael J, Jordan M, Vivas C, Starzl TE: Renal transplantation under FK506 in African-Americans: early experience. Transplant Proc 25:2468-2469, 1993.
http://d-scholarship.pitt.edu/4948/
6
256Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ: A prospective randomized trial of tacrolimus and prednisone vs. tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 66:1395-1398, 1998.
http://d-scholarship.pitt.edu/5433/
6
257Smith GV, Kolff J, Kashiwagi N, Putnam CW, Starzl TE: Modification of established rejection of canine kidney and liver homografts with antilymphocyte gamma-G globulin. Surgery 66:546-549, 1969.
http://d-scholarship.pitt.edu/3570/
5
258Zaghloul I, Burckart GJ, Starzl TE, Todo S, Ptachcinski RJ, Venkataramanan R: Cyclosporin G analysis and monitoring by high pressure liquid chromatography. Transplant Proc 18:771-773, 1986.
http://d-scholarship.pitt.edu/4050/
5
259Habucky K, Venkataramanan R, Ptachcinski RJ, Burckart GJ, Todo S, Starzl TE: Effect of chronic therapy on absorption and disposition of cyclosporine. Transplant Proc 20:162-163, 1988.
http://d-scholarship.pitt.edu/4253/
5
260Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Starzl TE: Prevention of spontaneous diabetes in the BB rat with FK 506. (to the Editor) Lancet 336:373-374, 1990.
http://d-scholarship.pitt.edu/4514/
5
261Farghali H, Sakr M, Gasbarrini A, Venkatat R, Gavaler J, Starzl TE, Van Thiel DH: Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. Transplant Proc 23:2802-2804, 1991.
http://d-scholarship.pitt.edu/4650/
5
262Whiteside TL, Wilson J, Bryant J, Zeevi A, Abu-Elmagd K, Jain A, Alessiani M, Fung J, Herberman RB, Starzl TE: Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. Transplant Proc 23:3047-3051, 1991.
http://d-scholarship.pitt.edu/4701/
5
263Cai X, Harnaha J, Rao PN, Flowers J, Venkataramanan R, Warty V, Fung JJ, Starzl TE: Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart and skin. Transplant Proc 24:1403-1405, 1992.
http://d-scholarship.pitt.edu/4873/
5
264Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, McCauley J, Johnston J, Randhawa P, Irish W, Gritsch HA, Naraghi R, Hakala TR, Fung JJ, Starzl TE: A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus –prednisone -mycophenolate mofetil in renal transplant recipients. Transplantation 67:411-415, 1999.
http://d-scholarship.pitt.edu/5408/
5
265Shapiro R, Scantlebury VP, Jordan ML, Vivas CA, Jain A, Hakala TR, McCauley J, Johnston J, Randhawa P, Fedorek S, Gray E, Chesky A, Dvorchik I, Donaldson J, Fung JJ, Starzl TE: A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc 34:1651-1652, 2002.
http://d-scholarship.pitt.edu/5567/
5
266Boggs S, Patrene K, Vecchini F, Markus P, Cooper M, Duquesnoy R, Starzl TE, Bloomer W: FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. Transplant Proc 23:3236-3237, 1991.
http://d-scholarship.pitt.edu/4639/
4
267Cooper MH, Gregory SH, Thomson AW, Fung JJ, Starzl TE, Wing EJ: Evaluation of the influence of FK 506, rapamycin and cyclosporine on processing and presentation of particulate antigen by macrophages: Assessment of a drug "carry over" effect. Transplant Proc 23:2957-2958, 1991.
http://d-scholarship.pitt.edu/4643/
4
268Lu L, Qian S, Starzl TE, Lynch DH, Thomson AW: Blocking of the B7-CD28 pathway increases the capacity of FasL+ (CD95L+) dendritic cells to kill alloactivated T cells. In: Dendritic Cells in Fundamental & Clinical Immunology (ed. Ricciardi-Castagnoli) Plenum Press, New York, 1997, pp. 275-282.
http://d-scholarship.pitt.edu/5449/
4
269Shapiro R, Basu A, Tan HP, Morgan C, Sharma V, Blisard D, Randhawa PS, Dvorchik I, McCauley J, Ellis D, Marsh JW, Webber S, Kurland G, McCurry K, Abu-Emlagd K, Mazariegos G, Starzl TE: Kidney after non-renal transplantation - the impact of alemtuzumab induction. Transplantation 88:799-802, 2009.
http://d-scholarship.pitt.edu/5634/
4
270Klintmalm G, Iwatsuki S, Kano T, Iwaki Y, Terasaki PI, Schroter GP, Koep L, Weil R, Starzl TE: Determinants of effectiveness of thoracic duct drainage for primary cadaver kidney transplantation. Transplant Proc 13:537-538, 1981.
http://d-scholarship.pitt.edu/3850/
3
271Starzl TE, Todo S, Demetris AJ, Fung JJ: Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kid Dis 31:(Suppl 1).S7-S14, 1998. http://d-scholarship.pitt.edu/5395/
http://d-scholarship.pitt.edu/5395/
3
272Tang JL, Aitouche A, Subbotin V, Salam A, Sun H, Gandhi C, Valdivia LA, Fung JJ, Starzl TE, Rao AS: Endothelin-1 receptor blockade and its effect on chronic rejection. Transplant Proc 31:1249, 1999.
http://d-scholarship.pitt.edu/5472/
3
273Takaya S, Iwatsuki S, Starzl TE, Zagloul I, Noguchi T, Ohmori Y, Burckart GJ, Ptachcinski RJ, Venkataramanan R: Experimental study about the influence of liver dysfunction upon cyclosporine pharmacokinetics. Transplant Proc 20:154-156, 1988.
http://d-scholarship.pitt.edu/4252/
2
274Jordan ML, Hignet S, Wright J, Hoffman RA, Starzl TE: Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. Transplant Proc 23:2950-2952, 1991.
http://d-scholarship.pitt.edu/4664/
2
275Prasad SJ, McCauley J, Salama G, Starzl TE, Murray SA: In vitro effects of cyclosporine and FK 506 on the renal cortex. Transplant Proc 23:3128-3129, 1991.
http://d-scholarship.pitt.edu/4676/
2
276Yagihashi A, Yoshida Y, Terasawa K, Ujike Y, Konno A, Ogura K, Kobayashi M, Takenaka T, Hayashi S, Selby R, Warty V, Noguchi K, Iwaki Y, Starzl TE: The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. Transplant Proc 23:2937-2938, 1991.
http://d-scholarship.pitt.edu/4704/
2
277Thomson AW, Woo J, Lemster B, Todo S, Fung JJ, Starzl TE: Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine. Transplant Proc 25:704-705, 1993.
http://d-scholarship.pitt.edu/4853/
2